Key Highlights
•
A new oral form of the chemotherapy drug paclitaxel (called DHP107) was found to be as effective as the standard intravenous (IV) version for treating HER2-negative breast cancer that has returned or spread. This is significant because the oral pill could eliminate the need for long IV infusions and reduce common side effects like severe allergic reactions and nerve damage.
Source →
•
For lung cancer patients with both an EGFR mutation and a tumor suppressor gene mutation, adding chemotherapy (carboplatin–pemetrexed) to the targeted drug aumolertinib significantly delayed cancer progression compared to the targeted drug alone. This finding provides the first prospective evidence for a more intensive, personalized treatment approach for this specific group of patients.
Source →
•
A large European study found that in patients with a type of autoimmune lung disease linked to ANCA antibodies, the severity of lung scarring seen on scans and lower lung function at diagnosis were key predictors of worse outcomes, including death. The study suggests that drugs like rituximab may help preserve lung function in these patients, highlighting the need for early diagnosis and tailored treatment.
Source →
•
Cardiac amyloidosis, a disease where abnormal proteins build up in the heart, can cause heart failure across the full range of heart pumping strength, not just in hearts with preserved function. Combining measurements of pumping strength, heart muscle strain, and blood flow creates a better model for predicting patient survival, arguing for a more comprehensive imaging approach.
Source →
•
A study confirmed that a lower, adjusted dose of the COVID-19 antiviral nirmatrelvir/ritonavir is safe and maintains effective drug levels in patients with severe kidney impairment, including those on dialysis. This is crucial as these patients are at high risk for severe COVID-19 but were previously excluded from treatment due to concerns about drug accumulation.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
